The Rush Lung Center (RLC) offers patients the opportunity to be involved in innovative and ground breaking research.

Rush is one of 24 North American participants in the Thoracic Surgery Oncology Group (TSOG). Formed in 2017 as an offshoot of the American Association for Thoracic Surgery, this cooperative group aims to accrue patients to investigator-initiated studies and select industry-sponsored clinical trials. The RLC is currently enrolling patients in two trials, TSOG 101 and TSOG 102.

TSOG 101 is a ctDNA study that evaluates circulating tumor DNA as a prognostic biomarker in patients who receive neoadjuvant therapy prior to surgery. TSOG 102 is a clinical registry of patients who have two or more ground glass opacities (GGOs) and receive CT scans as a standard of care every six months. These patients are followed for five years for their outcomes and survival.

**Inclusion Criteria**

**TSOG 101: ctDNA blood collection study**

- Stage II-IIIB patients ONLY receiving neoadjuvant therapy prior to surgery (any chemo/rad/immunotherapy)

**TSOG 102: Registry Trial of Active Surveillance for Multifocal Ground Glass Opacities (GGOs)**

- Have two or more GGOs on initial CT imaging
- GGOs must measure ≤3.0 cm and ≥0.6 cm in the greatest dimension
- Must not have any malignancy in past 3 years

If you are interested in learning more about these studies or would like to have a patient considered for enrollment, contact Abigail Goerge.

**Abigail Goerge**  
**RLC clinical research coordinator**  
**Tel:** (312)563-7267  
**Email:** abigail_k_goerge@rush.edu.